Cargando…

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

The purpose of the study was to assess the proportion of patients who achieve pain relief thresholds, the time needed to reach the thresholds, and the relationship between pain and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate in RA-BEAM (NCT01...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C., Lee, Yvonne C., Fleischmann, Roy, Takeuchi, Tsutomu, Perkins, Elizabeth L., Fautrel, Bruno, Zhu, Baojin, Quebe, Amanda K., Gaich, Carol L., Zhang, Xiang, Dickson, Christina L., Schlichting, Douglas E., Patel, Himanshu, Durand, Frederick, Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617097/
https://www.ncbi.nlm.nih.gov/pubmed/31212775
http://dx.doi.org/10.3390/jcm8060831
_version_ 1783433613108314112
author Taylor, Peter C.
Lee, Yvonne C.
Fleischmann, Roy
Takeuchi, Tsutomu
Perkins, Elizabeth L.
Fautrel, Bruno
Zhu, Baojin
Quebe, Amanda K.
Gaich, Carol L.
Zhang, Xiang
Dickson, Christina L.
Schlichting, Douglas E.
Patel, Himanshu
Durand, Frederick
Emery, Paul
author_facet Taylor, Peter C.
Lee, Yvonne C.
Fleischmann, Roy
Takeuchi, Tsutomu
Perkins, Elizabeth L.
Fautrel, Bruno
Zhu, Baojin
Quebe, Amanda K.
Gaich, Carol L.
Zhang, Xiang
Dickson, Christina L.
Schlichting, Douglas E.
Patel, Himanshu
Durand, Frederick
Emery, Paul
author_sort Taylor, Peter C.
collection PubMed
description The purpose of the study was to assess the proportion of patients who achieve pain relief thresholds, the time needed to reach the thresholds, and the relationship between pain and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate in RA-BEAM (NCT0170358). A randomized, double-blind trial was conducted, comparing baricitinib (N = 487), adalimumab (N = 330), and placebo (N = 488) plus methotrexate. Pain was evaluated by patient’s assessment on a 0–100 mm visual analog scale (VAS). The following were assessed through a 24-week placebo-controlled period: the proportion of patients who achieved ≥30%, ≥50%, and ≥70% pain relief, the time to achieve these pain relief thresholds, remaining pain (VAS ≤ 10 mm, ≤20 mm, or ≤40 mm), and the relationship between inflammation markers and pain relief. Baricitinib-treated patients were more likely (p < 0.05) to achieve ≥30%, ≥50%, and ≥70% pain relief than placebo- and adalimumab-treated patients, as early as Week 1 vs. placebo and at Week 4 vs. adalimumab. A greater proportion of baricitinib-treated patients achieved ≤20 mm or ≤40 mm remaining pain vs. placebo- and adalimumab-treated patients. Baricitinib-treated patients tended to demonstrate consistent pain relief independent of levels of inflammation control. In RA patients with an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than adalimumab and placebo. Analyses suggest the relationship between inflammation and pain may be different for baricitinib and adalimumab treatments.
format Online
Article
Text
id pubmed-6617097
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66170972019-07-18 Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial Taylor, Peter C. Lee, Yvonne C. Fleischmann, Roy Takeuchi, Tsutomu Perkins, Elizabeth L. Fautrel, Bruno Zhu, Baojin Quebe, Amanda K. Gaich, Carol L. Zhang, Xiang Dickson, Christina L. Schlichting, Douglas E. Patel, Himanshu Durand, Frederick Emery, Paul J Clin Med Article The purpose of the study was to assess the proportion of patients who achieve pain relief thresholds, the time needed to reach the thresholds, and the relationship between pain and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate in RA-BEAM (NCT0170358). A randomized, double-blind trial was conducted, comparing baricitinib (N = 487), adalimumab (N = 330), and placebo (N = 488) plus methotrexate. Pain was evaluated by patient’s assessment on a 0–100 mm visual analog scale (VAS). The following were assessed through a 24-week placebo-controlled period: the proportion of patients who achieved ≥30%, ≥50%, and ≥70% pain relief, the time to achieve these pain relief thresholds, remaining pain (VAS ≤ 10 mm, ≤20 mm, or ≤40 mm), and the relationship between inflammation markers and pain relief. Baricitinib-treated patients were more likely (p < 0.05) to achieve ≥30%, ≥50%, and ≥70% pain relief than placebo- and adalimumab-treated patients, as early as Week 1 vs. placebo and at Week 4 vs. adalimumab. A greater proportion of baricitinib-treated patients achieved ≤20 mm or ≤40 mm remaining pain vs. placebo- and adalimumab-treated patients. Baricitinib-treated patients tended to demonstrate consistent pain relief independent of levels of inflammation control. In RA patients with an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than adalimumab and placebo. Analyses suggest the relationship between inflammation and pain may be different for baricitinib and adalimumab treatments. MDPI 2019-06-12 /pmc/articles/PMC6617097/ /pubmed/31212775 http://dx.doi.org/10.3390/jcm8060831 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Taylor, Peter C.
Lee, Yvonne C.
Fleischmann, Roy
Takeuchi, Tsutomu
Perkins, Elizabeth L.
Fautrel, Bruno
Zhu, Baojin
Quebe, Amanda K.
Gaich, Carol L.
Zhang, Xiang
Dickson, Christina L.
Schlichting, Douglas E.
Patel, Himanshu
Durand, Frederick
Emery, Paul
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
title Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
title_full Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
title_fullStr Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
title_full_unstemmed Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
title_short Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
title_sort achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the ra-beam trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617097/
https://www.ncbi.nlm.nih.gov/pubmed/31212775
http://dx.doi.org/10.3390/jcm8060831
work_keys_str_mv AT taylorpeterc achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT leeyvonnec achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT fleischmannroy achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT takeuchitsutomu achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT perkinselizabethl achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT fautrelbruno achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT zhubaojin achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT quebeamandak achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT gaichcaroll achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT zhangxiang achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT dicksonchristinal achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT schlichtingdouglase achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT patelhimanshu achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT durandfrederick achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial
AT emerypaul achievingpaincontrolinrheumatoidarthritiswithbaricitiniboradalimumabplusmethotrexateresultsfromtherabeamtrial